| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
865,759 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
485,736 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,282,436 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
71 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dansey Roger D |
Chief Medical Officer |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
17,172 |
89,950 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-08-16 |
4 |
AS |
$154.55 |
$256,096 |
D/D |
(1,657) |
72,778 |
|
1% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,718 |
61,072 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-08-16 |
4 |
AS |
$154.55 |
$101,697 |
D/D |
(658) |
52,354 |
|
1% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-08-13 |
4 |
S |
$156.58 |
$1,565,867 |
D/D |
(10,000) |
74,435 |
|
-1% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-06 |
4 |
AS |
$159.26 |
$925,134 |
D/D |
(5,793) |
715,209 |
|
-7% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-06 |
4 |
OE |
$15.46 |
$89,560 |
D/D |
5,793 |
718,885 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-05 |
4 |
AS |
$162.02 |
$3,842,086 |
D/D |
(23,560) |
715,209 |
|
-11% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-05 |
4 |
OE |
$15.46 |
$364,238 |
D/D |
23,560 |
722,394 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-07-02 |
4 |
AS |
$158.41 |
$111,362 |
D/D |
(703) |
43,187 |
|
18% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-07-02 |
4 |
AS |
$155.70 |
$2,387,233 |
D/D |
(15,268) |
715,209 |
|
18% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-07-02 |
4 |
OE |
$15.46 |
$236,043 |
D/D |
15,268 |
720,400 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-07-01 |
4 |
AS |
$156.94 |
$2,222,376 |
D/D |
(14,085) |
715,209 |
|
20% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-07-01 |
4 |
OE |
$15.46 |
$217,754 |
D/D |
14,085 |
719,697 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-06-16 |
4 |
AS |
$152.22 |
$3,822,034 |
D/D |
(25,109) |
84,435 |
|
13% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-06-07 |
4 |
AS |
$150.00 |
$195,450 |
D/D |
(1,303) |
53,012 |
|
9% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-06-07 |
4 |
OE |
$26.10 |
$34,008 |
D/D |
1,303 |
54,315 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-06-03 |
4 |
AS |
$142.07 |
$4,241,801 |
D/D |
(29,353) |
715,209 |
|
10% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-06-03 |
4 |
OE |
$15.46 |
$453,797 |
D/D |
29,353 |
717,052 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-06-03 |
4 |
AS |
$142.42 |
$1,550,090 |
D/D |
(10,697) |
53,012 |
|
10% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-06-03 |
4 |
OE |
$15.46 |
$165,376 |
D/D |
10,697 |
63,709 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-05-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
66,936 |
120,605 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-05-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
76,877 |
53,012 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-05-17 |
4 |
AS |
$145.95 |
$48,746 |
D/D |
(334) |
43,890 |
|
9% |
|
| Seth Alpna |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
11,450 |
|
- |
|
952 Records found
|
|
Page 11 of 39 |
|
|
